Microtubule-Stabilizing Agent: Halichondrin B Analog (E7389)

Breast Diseases

Volumn 18, Issue 1, 2007, Pages 21-23

  Atieh, Deena M ^a   Vahdat, Linda T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947126655     PISSN: 1043321X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-321X(07)80004-X     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, Georgia. Available at http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2006.asp Accessed July, 2006.
2. Miller K., and Sledge Jr. G. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 13 (1999) 415-434
3. Stockler M., Wilcken N., Ghersi D., et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26 (2000) 151-168
4. Sjostrom J., Blomqvist C., Mouridsen H., et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35 (1999) 1194-1201
5. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16 (1998) 3439-3460
6. Chung C., and Carlson R. Goals and objectives in the management of metastatic breast cancer. Oncologist 8 (2003) 514-520
7. Falkson G., Holcroft C., Gelman R., et al. Ten-year follow-up study of premenopausal women with metastatic breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13 (1995) 1453-1458
8. Gennari A., Conte P., Rosso R., et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 104 (2005) 1742-1750
9. Sipkema D., Osinga R., Schatton W., et al. Large-scale production of pharmaceuticals by marine sponges: Sea, cell, or synthesis?. Biotechnol Bioeng 90 (2005) 201-222
10. Towle M., Salvato K., Budrow J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61 (2001) 1013-1021
11. Blum J., Jones S., Buzdar A., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
12. Honore S., Pasquier E., and Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62 (2005) 3039-3056
13. Bergstralh D., and Ting J. Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 32 (2006) 166-179
14. Johnson J., Williams G., and Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
15. Luduena R., Roach M., Prasad V., et al. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 45 (1993) 421-427
16. Hamel E. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55 (1992) 31-51
17. Wagner P., Wang B., Clark E., et al. Microtubule Associated Protein (MAP)-Tau: A novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 24 (2005) 1149-1152
18. van Oosterom A. Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer. Semin Oncol 22 (1995) 22-28
19. Ghersi D., Wilcken N., and Simes R. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93 (2005) 293-301
20. Low J., Wedam S., Lee J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 (2005) 2726-2734
21. Fojo A., and Menefee M. Microtubule targeting agents: Basic mechanisms of multidrug resistance (MDR). Semin Oncol 32 (2005) S3-S8
22. Bai R., Paull K., Herald C., et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266 (1991) 15882-15889
23. Fodstad O., Breistol K., Pettit G., et al. Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J Exp Ther Oncol 1 (1996) 119-125
24. Synold T., Morgan R., Newman E., et al. A phase 1 pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol 23 (2005) 3036
25. Blum J., Forero L., Heiskala M., et al. E7389, a novel anti-tubulin, in patients with refractory breast cancer. J Clin Oncol 24 (2006) 653